A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

  • participants needed
  • sponsor
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Updated on 12 September 2023
measurable disease
intensity-modulated radiation therapy
nasopharyngeal carcinoma


This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.

Condition Advanced Malignancies, Carcinoma, nasopharyngeal carcinoma, Nasopharyngeal Cancer, Vulvar Dysplasia and Carcinoma
Treatment Intensity Modulated Radiotherapy, TQB2450
Clinical Study IdentifierNCT04895345
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last Modified on12 September 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note